Blockchain Registration Transaction Record

Tonix Q2 Revenue Surges on TONMYA, Pipeline Advances

Tonix Pharmaceuticals reports Q2 2026 revenue surge to $13.5M driven by TONMYA sales, expands coverage to 136M lives, and advances pipeline in depression and Lyme disease.

This news matters because Tonix's strong TONMYA sales and expanded coverage indicate a significant commercial breakthrough for a new fibromyalgia treatment, which could improve outcomes for millions of patients. The company's advancing pipeline in major depressive disorder and Lyme disease prevention also holds potential for addressing major unmet medical needs. For investors, the revenue growth and cash position signal financial stability and growth prospects, making TNXP a stock to watch. For patients and healthcare providers, these developments could lead to new treatment options in the near future.